论文部分内容阅读
评价经皮穿刺微波凝固(PMCT)治疗原发性肝癌在大宗病例中的远期疗效。材料与方法,在超声引导下对234例原发性肝癌患者共339个结节进行PMCT,并观察其生存率。平均肿块大小4.10±1.92cm,随访最长7年零7个月,随访方式为定期景像复查(彩超、CT、MRI)及时治疗术后穿刺活检。结果:治疗后超声显示91.96%(263/286)的病灶血流消失,89.20%(190/213)的病灶增强CT无强化,89.13%(41/46)的病灶增强MRI无强化,194个结节治疗后活检,92.8%(180/194)显示肿瘤完全坏死5例。全组1-5年累计生存率分别为92.70%,81.60%,72.85%,66.37%和56.70%,生存率同肿瘤的分化程度和大小存在明显的相关生,全组未发生严重并发症。结论:PMCT治疗原发性肝癌安全有效,可使绝大多数块完全坏死,取得满意远期疗效。
To evaluate the long-term efficacy of percutaneous puncture microwave coagulation (PMCT) in the treatment of primary liver cancer in a large number of cases. Materials and Methods: PMCT was performed in 339 nodules of 234 patients with primary liver cancer under ultrasound guidance. The survival rate was also observed. The mean lump size was 4.10 ± 1.92cm. The patients were followed up for a maximum of 7 years and 7 months. The follow-up method was postoperative biopsy for regular imaging review (color Doppler ultrasound, CT, MRI). Results: After treatment, 91.96% (263/286) of the lesions showed no blood flow reduction, 89.20% (190/213) of the lesion enhanced CT no enhancement, 89.13% (41/46) lesion enhanced MRI without enhancement, 194 knots After the biopsy, 92.8% (180/194) showed complete tumor necrosis in 5 cases. The overall 1-5 year cumulative survival rates were 92.70%, 81.60%, 72.85%, 66.37% and 56.70% respectively. There was a significant correlation between survival rate and tumor differentiation degree and size. No serious complications occurred in the whole group. Conclusion: PMCT is safe and effective in the treatment of primary liver cancer, which can completely block most of the masses and achieve satisfactory long-term efficacy.